#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Epilepsy is a disorder in the central nervous system ( CNS ) that is characterized by an increase in the number of electrical impulses that occurs in one focal locus of the brain and/or the entire brain , resulting in partial or generalized seizures .
2-1	16-24	Epilepsy	abstract	new	coref	2-3[3_0]
2-2	25-27	is	_	_	_	_
2-3	28-29	a	abstract[3]	giv[3]	coref	6-3[0_3]
2-4	30-38	disorder	abstract[3]	giv[3]	_	_
2-5	39-41	in	abstract[3]	giv[3]	_	_
2-6	42-45	the	abstract[3]|abstract[4]	giv[3]|new[4]	appos	2-11[0_4]
2-7	46-53	central	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-8	54-61	nervous	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-9	62-68	system	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-10	69-70	(	_	_	_	_
2-11	71-74	CNS	abstract	giv	_	_
2-12	75-76	)	_	_	_	_
2-13	77-81	that	_	_	_	_
2-14	82-84	is	_	_	_	_
2-15	85-98	characterized	_	_	_	_
2-16	99-101	by	_	_	_	_
2-17	102-104	an	event[6]	new[6]	_	_
2-18	105-113	increase	event[6]	new[6]	_	_
2-19	114-116	in	event[6]	new[6]	_	_
2-20	117-120	the	event[6]|abstract[7]	new[6]|new[7]	_	_
2-21	121-127	number	event[6]|abstract[7]	new[6]|new[7]	_	_
2-22	128-130	of	event[6]|abstract[7]	new[6]|new[7]	_	_
2-23	131-141	electrical	event[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-24	142-150	impulses	event[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-25	151-155	that	_	_	_	_
2-26	156-162	occurs	_	_	_	_
2-27	163-165	in	_	_	_	_
2-28	166-169	one	place[9]	new[9]	_	_
2-29	170-175	focal	place[9]	new[9]	_	_
2-30	176-181	locus	place[9]	new[9]	_	_
2-31	182-184	of	place[9]	new[9]	_	_
2-32	185-188	the	place[9]|object[10]	new[9]|new[10]	_	_
2-33	189-194	brain	place[9]|object[10]	new[9]|new[10]	_	_
2-34	195-201	and/or	place[9]|object[10]	new[9]|new[10]	_	_
2-35	202-205	the	place[9]|object[10]|object[11]	new[9]|new[10]|new[11]	coref	5-12[0_11]
2-36	206-212	entire	place[9]|object[10]|object[11]	new[9]|new[10]|new[11]	_	_
2-37	213-218	brain	place[9]|object[10]|object[11]	new[9]|new[10]|new[11]	_	_
2-38	219-220	,	_	_	_	_
2-39	221-230	resulting	_	_	_	_
2-40	231-233	in	_	_	_	_
2-41	234-241	partial	event[12]	new[12]	coref	5-5[24_12]
2-42	242-244	or	event[12]	new[12]	_	_
2-43	245-256	generalized	event[12]	new[12]	_	_
2-44	257-265	seizures	event[12]	new[12]	_	_
2-45	266-267	.	_	_	_	_

#Text=The administration of antiepileptic drugs is mostly done via the oral or intravenous routes .
3-1	268-271	The	event[13]	new[13]	coref	11-21[0_13]
3-2	272-286	administration	event[13]	new[13]	_	_
3-3	287-289	of	event[13]	new[13]	_	_
3-4	290-303	antiepileptic	event[13]|substance|substance[15]	new[13]|new|new[15]	coref|coref	7-1[0_15]|7-1[0_15]
3-5	304-309	drugs	event[13]|substance[15]	new[13]|new[15]	_	_
3-6	310-312	is	_	_	_	_
3-7	313-319	mostly	_	_	_	_
3-8	320-324	done	_	_	_	_
3-9	325-328	via	_	_	_	_
3-10	329-332	the	place[16]	new[16]	_	_
3-11	333-337	oral	place[16]	new[16]	_	_
3-12	338-340	or	place[16]	new[16]	_	_
3-13	341-352	intravenous	place[16]	new[16]	_	_
3-14	353-359	routes	place[16]	new[16]	_	_
3-15	360-361	.	_	_	_	_

#Text=Drug resistance at the late stage of therapy develops in about 40 % of patients .
4-1	362-366	Drug	substance|abstract[18]	new|new[18]	coref|coref|coref|coref	5-1[23_18]|7-22|5-1[23_18]|7-22
4-2	367-377	resistance	abstract[18]	new[18]	_	_
4-3	378-380	at	abstract[18]	new[18]	_	_
4-4	381-384	the	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-5	385-389	late	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-6	390-395	stage	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-7	396-398	of	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-8	399-406	therapy	abstract[18]|abstract[19]|event	new[18]|new[19]|new	_	_
4-9	407-415	develops	_	_	_	_
4-10	416-418	in	_	_	_	_
4-11	419-424	about	quantity[21]	new[21]	_	_
4-12	425-427	40	quantity[21]	new[21]	_	_
4-13	428-429	%	quantity[21]	new[21]	_	_
4-14	430-432	of	quantity[21]	new[21]	_	_
4-15	433-441	patients	quantity[21]|person	new[21]|new	coref	6-1[29_0]
4-16	442-443	.	_	_	_	_

#Text=Drug resistance leads to uncontrolled seizures , a higher risk of brain damage , and increased mortality rates .
5-1	444-448	Drug	abstract[23]	giv[23]	coref	7-22[44_23]
5-2	449-459	resistance	abstract[23]	giv[23]	_	_
5-3	460-465	leads	_	_	_	_
5-4	466-468	to	_	_	_	_
5-5	469-481	uncontrolled	event[24]	giv[24]	coref	6-11[0_24]
5-6	482-490	seizures	event[24]	giv[24]	_	_
5-7	491-492	,	_	_	_	_
5-8	493-494	a	abstract[25]	new[25]	_	_
5-9	495-501	higher	abstract[25]	new[25]	_	_
5-10	502-506	risk	abstract[25]	new[25]	_	_
5-11	507-509	of	abstract[25]	new[25]	_	_
5-12	510-515	brain	abstract[25]|object|abstract[27]	new[25]|giv|new[27]	coref|coref	8-19|8-19
5-13	516-522	damage	abstract[25]|abstract[27]	new[25]|new[27]	_	_
5-14	523-524	,	_	_	_	_
5-15	525-528	and	_	_	_	_
5-16	529-538	increased	_	_	_	_
5-17	539-548	mortality	abstract[28]	new[28]	_	_
5-18	549-554	rates	abstract[28]	new[28]	_	_
5-19	555-556	.	_	_	_	_

#Text=Patients with epilepsy suffer from emotional and behavioral changes , seizures , convulsions , muscular spasms , depression and , in some cases , unconsciousness .
6-1	557-565	Patients	person[29]	giv[29]	_	_
6-2	566-570	with	person[29]	giv[29]	_	_
6-3	571-579	epilepsy	person[29]|abstract	giv[29]|giv	coref	7-7
6-4	580-586	suffer	_	_	_	_
6-5	587-591	from	_	_	_	_
6-6	592-601	emotional	abstract[31]	new[31]	_	_
6-7	602-605	and	abstract[31]	new[31]	_	_
6-8	606-616	behavioral	abstract[31]	new[31]	_	_
6-9	617-624	changes	abstract[31]	new[31]	_	_
6-10	625-626	,	_	_	_	_
6-11	627-635	seizures	event	giv	_	_
6-12	636-637	,	_	_	_	_
6-13	638-649	convulsions	abstract	new	_	_
6-14	650-651	,	_	_	_	_
6-15	652-660	muscular	abstract[34]	new[34]	_	_
6-16	661-667	spasms	abstract[34]	new[34]	_	_
6-17	668-669	,	_	_	_	_
6-18	670-680	depression	abstract	new	_	_
6-19	681-684	and	_	_	_	_
6-20	685-686	,	_	_	_	_
6-21	687-689	in	_	_	_	_
6-22	690-694	some	abstract[36]	new[36]	_	_
6-23	695-700	cases	abstract[36]	new[36]	_	_
6-24	701-702	,	_	_	_	_
6-25	703-718	unconsciousness	_	_	_	_
6-26	719-720	.	_	_	_	_

#Text=Drugs used for the treatment of epilepsy have poor bioavailability and eventually become ineffective over the course of treatment due to drug resistance .
7-1	721-726	Drugs	substance	giv	coref	9-6[57_0]
7-2	727-731	used	_	_	_	_
7-3	732-735	for	_	_	_	_
7-4	736-739	the	event[38]	new[38]	coref	7-19[42_38]
7-5	740-749	treatment	event[38]	new[38]	_	_
7-6	750-752	of	event[38]	new[38]	_	_
7-7	753-761	epilepsy	event[38]|abstract	new[38]|giv	coref	8-1
7-8	762-766	have	_	_	_	_
7-9	767-771	poor	substance[40]	new[40]	coref	11-1[73_40]
7-10	772-787	bioavailability	substance[40]	new[40]	_	_
7-11	788-791	and	_	_	_	_
7-12	792-802	eventually	_	_	_	_
7-13	803-809	become	_	_	_	_
7-14	810-821	ineffective	_	_	_	_
7-15	822-826	over	_	_	_	_
7-16	827-830	the	event[41]	new[41]	_	_
7-17	831-837	course	event[41]	new[41]	_	_
7-18	838-840	of	event[41]	new[41]	_	_
7-19	841-850	treatment	event[41]|event[42]	new[41]|giv[42]	coref	8-1[46_42]
7-20	851-854	due	event[41]|event[42]	new[41]|giv[42]	_	_
7-21	855-857	to	_	_	_	_
7-22	858-862	drug	substance|abstract[44]	giv|giv[44]	coref|coref	8-12[48_0]|8-12[48_0]
7-23	863-873	resistance	abstract[44]	giv[44]	_	_
7-24	874-875	.	_	_	_	_

#Text=Epilepsy treatment is often complicated due to the poor release of the drug through the adjunctive blood – brain barrier , which may be overcome by the preparation of the drug as solid lipid nanoparticles .
8-1	876-884	Epilepsy	abstract|event[46]	giv|giv[46]	coref|coref	17-16|17-16
8-2	885-894	treatment	event[46]	giv[46]	_	_
8-3	895-897	is	_	_	_	_
8-4	898-903	often	_	_	_	_
8-5	904-915	complicated	_	_	_	_
8-6	916-919	due	_	_	_	_
8-7	920-922	to	_	_	_	_
8-8	923-926	the	event[47]	new[47]	coref	9-13[60_47]
8-9	927-931	poor	event[47]	new[47]	_	_
8-10	932-939	release	event[47]	new[47]	_	_
8-11	940-942	of	event[47]	new[47]	_	_
8-12	943-946	the	event[47]|substance[48]	new[47]|giv[48]	coref	8-30[53_48]
8-13	947-951	drug	event[47]|substance[48]	new[47]|giv[48]	_	_
8-14	952-959	through	event[47]	new[47]	_	_
8-15	960-963	the	event[47]|substance[49]	new[47]|new[49]	_	_
8-16	964-974	adjunctive	event[47]|substance[49]	new[47]|new[49]	_	_
8-17	975-980	blood	event[47]|substance[49]	new[47]|new[49]	_	_
8-18	981-982	–	_	_	_	_
8-19	983-988	brain	object|object[51]	giv|new[51]	coref|coref	9-22[62_0]|9-22[62_0]
8-20	989-996	barrier	object[51]	new[51]	_	_
8-21	997-998	,	_	_	_	_
8-22	999-1004	which	_	_	_	_
8-23	1005-1008	may	_	_	_	_
8-24	1009-1011	be	_	_	_	_
8-25	1012-1020	overcome	_	_	_	_
8-26	1021-1023	by	_	_	_	_
8-27	1024-1027	the	abstract[52]	new[52]	_	_
8-28	1028-1039	preparation	abstract[52]	new[52]	_	_
8-29	1040-1042	of	abstract[52]	new[52]	_	_
8-30	1043-1046	the	abstract[52]|substance[53]	new[52]|giv[53]	coref	9-16[0_53]
8-31	1047-1051	drug	abstract[52]|substance[53]	new[52]|giv[53]	_	_
8-32	1052-1054	as	abstract[52]|substance[53]	new[52]|giv[53]	_	_
8-33	1055-1060	solid	abstract[52]|substance[53]	new[52]|giv[53]	_	_
8-34	1061-1066	lipid	abstract[52]|substance[53]|person	new[52]|giv[53]|new	coref	13-2
8-35	1067-1080	nanoparticles	abstract[52]|substance[53]	new[52]|giv[53]	_	_
8-36	1081-1082	.	_	_	_	_

#Text=The ideal delivery systems of antiepileptic drugs are the ones which provide localized and controlled drug release to targeted sites in the brain , which helps to reduce drug-associated toxicities and enhances the efficacy of the drug .
9-1	1083-1086	The	object[56]	new[56]	coref	9-9[58_56]
9-2	1087-1092	ideal	object[56]	new[56]	_	_
9-3	1093-1101	delivery	abstract|object[56]	new|new[56]	coref	19-14[134_0]
9-4	1102-1109	systems	object[56]	new[56]	_	_
9-5	1110-1112	of	object[56]	new[56]	_	_
9-6	1113-1126	antiepileptic	object[56]|substance[57]	new[56]|giv[57]	coref	16-18[113_57]
9-7	1127-1132	drugs	object[56]|substance[57]	new[56]|giv[57]	_	_
9-8	1133-1136	are	_	_	_	_
9-9	1137-1140	the	object[58]	giv[58]	coref	13-12[91_58]
9-10	1141-1145	ones	object[58]	giv[58]	_	_
9-11	1146-1151	which	_	_	_	_
9-12	1152-1159	provide	_	_	_	_
9-13	1160-1169	localized	event[60]	giv[60]	_	_
9-14	1170-1173	and	event[60]	giv[60]	_	_
9-15	1174-1184	controlled	event[60]	giv[60]	_	_
9-16	1185-1189	drug	substance|event[60]	giv|giv[60]	coref	9-36[65_0]
9-17	1190-1197	release	event[60]	giv[60]	_	_
9-18	1198-1200	to	event[60]	giv[60]	_	_
9-19	1201-1209	targeted	event[60]|place[61]	giv[60]|new[61]	_	_
9-20	1210-1215	sites	event[60]|place[61]	giv[60]|new[61]	_	_
9-21	1216-1218	in	event[60]|place[61]	giv[60]|new[61]	_	_
9-22	1219-1222	the	event[60]|place[61]|object[62]	giv[60]|new[61]|giv[62]	coref	12-11[0_62]
9-23	1223-1228	brain	event[60]|place[61]|object[62]	giv[60]|new[61]|giv[62]	_	_
9-24	1229-1230	,	_	_	_	_
9-25	1231-1236	which	_	_	_	_
9-26	1237-1242	helps	_	_	_	_
9-27	1243-1245	to	_	_	_	_
9-28	1246-1252	reduce	_	_	_	_
9-29	1253-1268	drug-associated	abstract[63]	new[63]	_	_
9-30	1269-1279	toxicities	abstract[63]	new[63]	_	_
9-31	1280-1283	and	_	_	_	_
9-32	1284-1292	enhances	_	_	_	_
9-33	1293-1296	the	abstract[64]	new[64]	coref	17-10[119_64]
9-34	1297-1305	efficacy	abstract[64]	new[64]	_	_
9-35	1306-1308	of	abstract[64]	new[64]	_	_
9-36	1309-1312	the	abstract[64]|substance[65]	new[64]|giv[65]	_	_
9-37	1313-1317	drug	abstract[64]|substance[65]	new[64]|giv[65]	_	_
9-38	1318-1319	.	_	_	_	_

#Text=Carbamazepine ( CBZ ) is an antiepileptic drug with a narrow therapeutic index , and it is poorly absorbed when taken by the oral route .
10-1	1320-1333	Carbamazepine	substance	new	coref	10-6[68_0]
10-2	1334-1335	(	_	_	_	_
10-3	1336-1339	CBZ	object	new	coref	21-23[152_0]
10-4	1340-1341	)	_	_	_	_
10-5	1342-1344	is	_	_	_	_
10-6	1345-1347	an	substance[68]	giv[68]	ana	11-1[0_68]
10-7	1348-1361	antiepileptic	substance[68]	giv[68]	_	_
10-8	1362-1366	drug	substance[68]	giv[68]	_	_
10-9	1367-1371	with	substance[68]	giv[68]	_	_
10-10	1372-1373	a	substance[68]|abstract[69]	giv[68]|new[69]	ana	10-16[0_69]
10-11	1374-1380	narrow	substance[68]|abstract[69]	giv[68]|new[69]	_	_
10-12	1381-1392	therapeutic	substance[68]|abstract[69]	giv[68]|new[69]	_	_
10-13	1393-1398	index	substance[68]|abstract[69]	giv[68]|new[69]	_	_
10-14	1399-1400	,	_	_	_	_
10-15	1401-1404	and	_	_	_	_
10-16	1405-1407	it	abstract	giv	_	_
10-17	1408-1410	is	_	_	_	_
10-18	1411-1417	poorly	_	_	_	_
10-19	1418-1426	absorbed	_	_	_	_
10-20	1427-1431	when	_	_	_	_
10-21	1432-1437	taken	_	_	_	_
10-22	1438-1440	by	_	_	_	_
10-23	1441-1444	the	event[71]	new[71]	_	_
10-24	1445-1449	oral	event[71]	new[71]	_	_
10-25	1450-1455	route	event[71]	new[71]	_	_
10-26	1456-1457	.	_	_	_	_

#Text=Its oral bioavailability is 75 % , and its maximum achieved plasma concentration is about 4 – 8 h after administration .
11-1	1458-1461	Its	substance|quantity[73]	giv|giv[73]	coref|ana|coref|ana	11-5[74_73]|11-9|11-5[74_73]|11-9
11-2	1462-1466	oral	quantity[73]	giv[73]	_	_
11-3	1467-1482	bioavailability	quantity[73]	giv[73]	_	_
11-4	1483-1485	is	_	_	_	_
11-5	1486-1488	75	quantity[74]	giv[74]	coref	16-14[112_74]
11-6	1489-1490	%	quantity[74]	giv[74]	_	_
11-7	1491-1492	,	quantity[74]	giv[74]	_	_
11-8	1493-1496	and	quantity[74]	giv[74]	_	_
11-9	1497-1500	its	quantity[74]|substance|quantity[77]	giv[74]|giv|new[77]	coref|coref|coref|coref	11-15[79_77]|12-1|11-15[79_77]|12-1
11-10	1501-1508	maximum	quantity[74]|quantity[77]	giv[74]|new[77]	_	_
11-11	1509-1517	achieved	quantity[74]|quantity[77]	giv[74]|new[77]	_	_
11-12	1518-1524	plasma	quantity[74]|substance|quantity[77]	giv[74]|new|new[77]	_	_
11-13	1525-1538	concentration	quantity[74]|quantity[77]	giv[74]|new[77]	_	_
11-14	1539-1541	is	quantity[74]	giv[74]	_	_
11-15	1542-1547	about	quantity[74]|quantity[79]	giv[74]|giv[79]	_	_
11-16	1548-1549	4	quantity[74]|quantity[79]	giv[74]|giv[79]	_	_
11-17	1550-1551	–	quantity[74]|quantity[79]	giv[74]|giv[79]	_	_
11-18	1552-1553	8	quantity[74]|quantity|quantity[79]	giv[74]|new|giv[79]	_	_
11-19	1554-1555	h	quantity[74]|quantity[79]	giv[74]|giv[79]	_	_
11-20	1556-1561	after	quantity[74]|quantity[79]	giv[74]|giv[79]	_	_
11-21	1562-1576	administration	quantity[74]|quantity[79]|event	giv[74]|giv[79]|giv	_	_
11-22	1577-1578	.	_	_	_	_

#Text=Carbamazepine acts through the inactivation of sodium channels , making brain cells less excitable .
12-1	1579-1592	Carbamazepine	substance	giv	coref	15-19
12-2	1593-1597	acts	_	_	_	_
12-3	1598-1605	through	_	_	_	_
12-4	1606-1609	the	event[82]	new[82]	_	_
12-5	1610-1622	inactivation	event[82]	new[82]	_	_
12-6	1623-1625	of	event[82]	new[82]	_	_
12-7	1626-1632	sodium	event[82]|substance|place[84]	new[82]|new|new[84]	_	_
12-8	1633-1641	channels	event[82]|place[84]	new[82]|new[84]	_	_
12-9	1642-1643	,	_	_	_	_
12-10	1644-1650	making	_	_	_	_
12-11	1651-1656	brain	object|object[86]	giv|new[86]	_	_
12-12	1657-1662	cells	object[86]	new[86]	_	_
12-13	1663-1667	less	_	_	_	_
12-14	1668-1677	excitable	_	_	_	_
12-15	1678-1679	.	_	_	_	_

#Text=Solid lipid nanoparticles ( SLNs ) are considered an alternative to colloidal systems like liposome , noisome and polymeric nanoparticles .
13-1	1680-1685	Solid	object[88]	new[88]	coref	13-20[0_88]
13-2	1686-1691	lipid	person|object[88]	giv|new[88]	coref	17-7
13-3	1692-1705	nanoparticles	object[88]	new[88]	_	_
13-4	1706-1707	(	_	_	_	_
13-5	1708-1712	SLNs	abstract	new	coref	14-1
13-6	1713-1714	)	_	_	_	_
13-7	1715-1718	are	_	_	_	_
13-8	1719-1729	considered	_	_	_	_
13-9	1730-1732	an	abstract[90]	new[90]	_	_
13-10	1733-1744	alternative	abstract[90]	new[90]	_	_
13-11	1745-1747	to	abstract[90]	new[90]	_	_
13-12	1748-1757	colloidal	abstract[90]|object[91]	new[90]|giv[91]	_	_
13-13	1758-1765	systems	abstract[90]|object[91]	new[90]|giv[91]	_	_
13-14	1766-1770	like	abstract[90]|object[91]	new[90]|giv[91]	_	_
13-15	1771-1779	liposome	abstract[90]|object[91]|object	new[90]|giv[91]|new	_	_
13-16	1780-1781	,	abstract[90]|object[91]	new[90]|giv[91]	_	_
13-17	1782-1789	noisome	abstract[90]|object[91]	new[90]|giv[91]	_	_
13-18	1790-1793	and	abstract[90]|object[91]	new[90]|giv[91]	_	_
13-19	1794-1803	polymeric	abstract[90]|object[91]	new[90]|giv[91]	_	_
13-20	1804-1817	nanoparticles	abstract[90]|object[91]|object	new[90]|giv[91]|giv	coref	17-6[118_0]
13-21	1818-1819	.	_	_	_	_

#Text=SLNs consist of solid lipids , which act as a stabilizer when dispersed in water in the presence of a surfactant .
14-1	1820-1824	SLNs	object	giv	_	_
14-2	1825-1832	consist	_	_	_	_
14-3	1833-1835	of	_	_	_	_
14-4	1836-1841	solid	object[95]	new[95]	_	_
14-5	1842-1848	lipids	object[95]	new[95]	_	_
14-6	1849-1850	,	_	_	_	_
14-7	1851-1856	which	_	_	_	_
14-8	1857-1860	act	_	_	_	_
14-9	1861-1863	as	_	_	_	_
14-10	1864-1865	a	_	_	_	_
14-11	1866-1876	stabilizer	_	_	_	_
14-12	1877-1881	when	_	_	_	_
14-13	1882-1891	dispersed	_	_	_	_
14-14	1892-1894	in	_	_	_	_
14-15	1895-1900	water	substance	new	_	_
14-16	1901-1903	in	_	_	_	_
14-17	1904-1907	the	abstract[97]	new[97]	_	_
14-18	1908-1916	presence	abstract[97]	new[97]	_	_
14-19	1917-1919	of	abstract[97]	new[97]	_	_
14-20	1920-1921	a	abstract[97]|substance[98]	new[97]|new[98]	_	_
14-21	1922-1932	surfactant	abstract[97]|substance[98]	new[97]|new[98]	_	_
14-22	1933-1934	.	_	_	_	_

#Text=SLN is characterized by its small size ( nano range ) , large surface area , and high drug loading capacity .
15-1	1935-1938	SLN	event	new	ana	15-5
15-2	1939-1941	is	_	_	_	_
15-3	1942-1955	characterized	_	_	_	_
15-4	1956-1958	by	_	_	_	_
15-5	1959-1962	its	event|quantity[101]	giv|new[101]	appos|appos	15-9[103_101]|15-9[103_101]
15-6	1963-1968	small	quantity[101]	new[101]	_	_
15-7	1969-1973	size	quantity[101]	new[101]	_	_
15-8	1974-1975	(	_	_	_	_
15-9	1976-1980	nano	object|quantity[103]	new|giv[103]	coref|coref	21-13[150_103]|21-13[150_103]
15-10	1981-1986	range	quantity[103]	giv[103]	_	_
15-11	1987-1988	)	_	_	_	_
15-12	1989-1990	,	_	_	_	_
15-13	1991-1996	large	quantity[105]	new[105]	_	_
15-14	1997-2004	surface	place|quantity[105]	new|new[105]	_	_
15-15	2005-2009	area	quantity[105]	new[105]	_	_
15-16	2010-2011	,	_	_	_	_
15-17	2012-2015	and	_	_	_	_
15-18	2016-2020	high	abstract[108]	new[108]	ana	16-4[0_108]
15-19	2021-2025	drug	substance|abstract[108]	giv|new[108]	coref	18-2
15-20	2026-2033	loading	quantity|abstract[108]	new|new[108]	_	_
15-21	2034-2042	capacity	abstract[108]	new[108]	_	_
15-22	2043-2044	.	_	_	_	_

#Text=In addition , it improves drug stability and has the ability to improve the oral bioavailability of poorly water-soluble drugs .
16-1	2045-2047	In	_	_	_	_
16-2	2048-2056	addition	_	_	_	_
16-3	2057-2058	,	_	_	_	_
16-4	2059-2061	it	abstract	giv	coref	16-10[111_0]
16-5	2062-2070	improves	_	_	_	_
16-6	2071-2075	drug	abstract[110]	new[110]	_	_
16-7	2076-2085	stability	abstract[110]	new[110]	_	_
16-8	2086-2089	and	_	_	_	_
16-9	2090-2093	has	_	_	_	_
16-10	2094-2097	the	abstract[111]	giv[111]	_	_
16-11	2098-2105	ability	abstract[111]	giv[111]	_	_
16-12	2106-2108	to	_	_	_	_
16-13	2109-2116	improve	_	_	_	_
16-14	2117-2120	the	substance[112]	giv[112]	coref	21-8[148_112]
16-15	2121-2125	oral	substance[112]	giv[112]	_	_
16-16	2126-2141	bioavailability	substance[112]	giv[112]	_	_
16-17	2142-2144	of	substance[112]	giv[112]	_	_
16-18	2145-2151	poorly	substance[112]|substance[113]	giv[112]|giv[113]	_	_
16-19	2152-2165	water-soluble	substance[112]|substance[113]	giv[112]|giv[113]	_	_
16-20	2166-2171	drugs	substance[112]|substance[113]	giv[112]|giv[113]	_	_
16-21	2172-2173	.	_	_	_	_

#Text=Gangurde and Kumar prepared lamotrigine solid lipid nanoparticles with a high efficacy for treatment of epilepsy . Nair et al.
17-1	2174-2182	Gangurde	person	new	_	_
17-2	2183-2186	and	_	_	_	_
17-3	2187-2192	Kumar	person	new	coref	18-12
17-4	2193-2201	prepared	_	_	_	_
17-5	2202-2213	lamotrigine	object	new	_	_
17-6	2214-2219	solid	object[118]	giv[118]	coref	18-3[125_118]
17-7	2220-2225	lipid	person|object[118]	giv|giv[118]	coref	18-4
17-8	2226-2239	nanoparticles	object[118]	giv[118]	_	_
17-9	2240-2244	with	_	_	_	_
17-10	2245-2246	a	abstract[119]	giv[119]	_	_
17-11	2247-2251	high	abstract[119]	giv[119]	_	_
17-12	2252-2260	efficacy	abstract[119]	giv[119]	_	_
17-13	2261-2264	for	abstract[119]	giv[119]	_	_
17-14	2265-2274	treatment	abstract[119]|abstract[120]	giv[119]|new[120]	_	_
17-15	2275-2277	of	abstract[119]|abstract[120]	giv[119]|new[120]	_	_
17-16	2278-2286	epilepsy	abstract[119]|abstract[120]|abstract	giv[119]|new[120]|giv	_	_
17-17	2287-2288	.	_	_	_	_
17-18	2289-2293	Nair	person	new	_	_
17-19	2294-2296	et	_	_	_	_
17-20	2297-2300	al.	_	_	_	_

#Text=prepared carbamazepine solid lipid nanoparticles to improve its therapeutic effect . Kumar et al.
18-1	2301-2309	prepared	_	_	_	_
18-2	2310-2323	carbamazepine	substance	giv	ana	18-8
18-3	2324-2329	solid	object[125]	giv[125]	coref	19-2[130_125]
18-4	2330-2335	lipid	person|object[125]	giv|giv[125]	coref	19-3
18-5	2336-2349	nanoparticles	object[125]	giv[125]	_	_
18-6	2350-2352	to	_	_	_	_
18-7	2353-2360	improve	_	_	_	_
18-8	2361-2364	its	substance|abstract[127]	giv|new[127]	coref|coref	20-10|20-10
18-9	2365-2376	therapeutic	abstract[127]	new[127]	_	_
18-10	2377-2383	effect	abstract[127]	new[127]	_	_
18-11	2384-2385	.	_	_	_	_
18-12	2386-2391	Kumar	person	giv	_	_
18-13	2392-2394	et	_	_	_	_
18-14	2395-2398	al.	_	_	_	_

#Text=prepared solid lipid nanoparticles of methylthioadenosine for the management of neurological conditions via oral delivery .
19-1	2399-2407	prepared	_	_	_	_
19-2	2408-2413	solid	object[130]	giv[130]	coref	20-10[139_130]
19-3	2414-2419	lipid	person|object[130]	giv|giv[130]	coref	20-12
19-4	2420-2433	nanoparticles	object[130]	giv[130]	_	_
19-5	2434-2436	of	object[130]	giv[130]	_	_
19-6	2437-2456	methylthioadenosine	object[130]|substance	giv[130]|new	_	_
19-7	2457-2460	for	_	_	_	_
19-8	2461-2464	the	organization[132]	new[132]	_	_
19-9	2465-2475	management	organization[132]	new[132]	_	_
19-10	2476-2478	of	organization[132]	new[132]	_	_
19-11	2479-2491	neurological	organization[132]|abstract[133]	new[132]|new[133]	_	_
19-12	2492-2502	conditions	organization[132]|abstract[133]	new[132]|new[133]	_	_
19-13	2503-2506	via	organization[132]|abstract[133]	new[132]|new[133]	_	_
19-14	2507-2511	oral	organization[132]|abstract[133]|abstract[134]	new[132]|new[133]|giv[134]	_	_
19-15	2512-2520	delivery	organization[132]|abstract[133]|abstract[134]	new[132]|new[133]|giv[134]	_	_
19-16	2521-2522	.	_	_	_	_

#Text=The objective of the current study was to prepare carbamazepine solid lipid nanoparticles ( CBZ-SLNs ) as a novel and alternative method for other colloidal dispersion carriers .
20-1	2523-2526	The	abstract[135]	new[135]	_	_
20-2	2527-2536	objective	abstract[135]	new[135]	_	_
20-3	2537-2539	of	abstract[135]	new[135]	_	_
20-4	2540-2543	the	abstract[135]|event[136]	new[135]|new[136]	coref	21-1[144_136]
20-5	2544-2551	current	abstract[135]|event[136]	new[135]|new[136]	_	_
20-6	2552-2557	study	abstract[135]|event[136]	new[135]|new[136]	_	_
20-7	2558-2561	was	_	_	_	_
20-8	2562-2564	to	_	_	_	_
20-9	2565-2572	prepare	_	_	_	_
20-10	2573-2586	carbamazepine	animal|object[139]	giv|giv[139]	appos|appos	20-15[0_139]|20-15[0_139]
20-11	2587-2592	solid	object[139]	giv[139]	_	_
20-12	2593-2598	lipid	person|object[139]	giv|giv[139]	_	_
20-13	2599-2612	nanoparticles	object[139]	giv[139]	_	_
20-14	2613-2614	(	_	_	_	_
20-15	2615-2623	CBZ-SLNs	object	giv	_	_
20-16	2624-2625	)	_	_	_	_
20-17	2626-2628	as	_	_	_	_
20-18	2629-2630	a	_	_	_	_
20-19	2631-2636	novel	_	_	_	_
20-20	2637-2640	and	_	_	_	_
20-21	2641-2652	alternative	_	_	_	_
20-22	2653-2659	method	_	_	_	_
20-23	2660-2663	for	_	_	_	_
20-24	2664-2669	other	object[143]	new[143]	_	_
20-25	2670-2679	colloidal	object|object[143]	new|new[143]	_	_
20-26	2680-2690	dispersion	abstract|object[143]	new|new[143]	_	_
20-27	2691-2699	carriers	object[143]	new[143]	_	_
20-28	2700-2701	.	_	_	_	_

#Text=The study aimed to prepare CBZ-SLNs with high entrapment efficiency % , small particle size , and high anticonvulsant activity compared to free CBZ .
21-1	2702-2705	The	event[144]	giv[144]	_	_
21-2	2706-2711	study	event[144]	giv[144]	_	_
21-3	2712-2717	aimed	_	_	_	_
21-4	2718-2720	to	_	_	_	_
21-5	2721-2728	prepare	_	_	_	_
21-6	2729-2737	CBZ-SLNs	substance[145]	new[145]	_	_
21-7	2738-2742	with	substance[145]	new[145]	_	_
21-8	2743-2747	high	substance[145]|quantity[148]	new[145]|giv[148]	_	_
21-9	2748-2758	entrapment	substance[145]|quantity|quantity[148]	new[145]|new|giv[148]	_	_
21-10	2759-2769	efficiency	substance[145]|abstract|quantity[148]	new[145]|new|giv[148]	_	_
21-11	2770-2771	%	substance[145]|quantity[148]	new[145]|giv[148]	_	_
21-12	2772-2773	,	substance[145]	new[145]	_	_
21-13	2774-2779	small	substance[145]|quantity[150]	new[145]|giv[150]	_	_
21-14	2780-2788	particle	substance[145]|object|quantity[150]	new[145]|new|giv[150]	_	_
21-15	2789-2793	size	substance[145]|quantity[150]	new[145]|giv[150]	_	_
21-16	2794-2795	,	substance[145]	new[145]	_	_
21-17	2796-2799	and	substance[145]	new[145]	_	_
21-18	2800-2804	high	substance[145]|abstract[151]	new[145]|new[151]	_	_
21-19	2805-2819	anticonvulsant	substance[145]|abstract[151]	new[145]|new[151]	_	_
21-20	2820-2828	activity	substance[145]|abstract[151]	new[145]|new[151]	_	_
21-21	2829-2837	compared	_	_	_	_
21-22	2838-2840	to	_	_	_	_
21-23	2841-2845	free	object[152]	giv[152]	_	_
21-24	2846-2849	CBZ	object[152]	giv[152]	_	_
21-25	2850-2851	.	_	_	_	_
